This review summarizes work that has been published recently in several papers reporting the effects of famciclovir and valaciclovir therapy on the establishment of herpes simplex virus (HSV) latency in a murine cutaneous infection model. For both HSV-1 and HSV-2 injections, therapy with famciclovir or valaciclovir from 1 or 2 days after virus inoculation reduced the ability to reactivate infectious virus from explanted ganglia when this was attempted several weeks after the primary infection. For famciclovir l the reduced ability to reactivate virus was also apparent in mice in which the onset of therapy was delayed for up to 3-5 days after virus inoculation. When more sensitive methods were employed to detect lotency, all mice were found to be positive for latent infections in the ganglial including those from mice receiving early therapy. However, for mice that had received oral famciclovir treatment the relative number of latently infected ganglion cells, as determined by infectious centres, appeared to be greatly reduced; this is thought to explain the failure to reactivate virus by means of the explant method. These results show a marked difference in activity between famciclovir and valaciclovir in this model and suggest that prompt therapy of first episode herpes by means of famciclovir may be able to reduce the establishment of latency in humans, where the establishment of latent infections in ganglionic neurons is thought to be a slower process than that observed in mice.
It is well known that in humans, soon after primary infection with either herpes simplex virus (HSV) type 1 or type 2 is initiated, a latent infection is established in the trigeminal or lumbar-sacral dorsal root ganglia. The process by which virus enters the sensory nerves and travels from the site of virus replication in the skin or mucus membranes cannot be determined directly in humans. However, much information has been inferred from the study of animal models and the study of organs in infected cultures.
Animal models for HSV latency
In the early 1970s it was first shown by Stevens and colleagues (Stevens & Cook, 1971 ) that if mice were infected with HSV in the foot-pad, latent infection was established in the corresponding dorsal root ganglia. If these ganglia were explanted a few weeks later, they contained no infectious virus. However, reactivation occurred on explantation, and after 1 week of incubation in vitro infectious virus could be cultivated from the homogenized tissue.
From this work and that of others a number of facts were established. The rate of retrograde transport was approximately 1.8 mm h-1 -corresponding to the rate of slow intra-axonal retrograde transport (Kristensson et al., 1974) . It appeared that large inoculum doses led to the direct uptake of virus into the axons (Field & Hill, 1975) but it was likely that moderate or small doses required virus replication in the inoculation site. The replication cycle ofHSV is approximately 12-24 h (Roizman & Sears, 1996) .
The establishment of latency does not require productive infection
Virus replication is not a prerequisite for the establishment of neuronal latency (McLennan & Darby, 1980) (Fig. 1) . In any case, virus is likely to enter the ganglia of mice within 1-2 days ofinoculation and the first latently infected cells are likely to be established by this time (Fig. 2) . The extent to which further neurons are colonized over the next few days of the infection is uncertain. Moreover, anteretrograde (rapid) flow of virus from the ganglia contributes to --------------~-- HSV infection of the hostcell HSV virus replication at the peripheral site and results in further spread of the virus from the ipsilateral ganglia into the CNS and on to the contralateral ganglia. But, as stated above, it appears that the establishment oflatency does not require virus replication in the ganglionic neurons (Roizman & Sears, 1996) . The extent of active virus replication in murine ganglionic neurons may represent an important difference between the human case and the murine model. It is not certain whether productive virus replication occurs in human ganglionic neurons, nor is it known whether virus readily spreads into CNS neurons in humans as is the case in mice (Fig. 2) . et al., 1989) . In situ hybridization has not been sufficiendy sensitive to detect latent HSV DNA, whose presence in the cell can, however, be confirmed using solution hybridization or polymerase chain reaction (PCR) amplification.
Comparison between HSV latency in animal models and humans
All information on the relationship between HSV and ganglionic cells in humans is derived from observing the patterns of recurrent disease following natural, surgical or in some cases experimental stimuli, and from the study of human tissues obtained at post mortem (Croen et al., 1987; Gordon et al., 1988; Krause et al., 1988; Stevens et al., 1988; Wechsler et al., 1988) . The trigeminal ganglia have been confirmed to be an important site of latency in humans. When cells expressing LAT are observed, the DNA appears to lack genetic termini during latency. Once latency is established it has proved very difficult to induce reproducible reactivations in vivo in mice. However, exp1antation of ganglia appears to act as a powerful reactivation stimulus and the presence of infectious virus can readily be detected in latently infected ganglion tissue within a few days of exp1antation. The molecular relationship established between HSV and human neurons following natural infection can only be inferred from the study oflatent infections in suitable animal models, which include mice inoculated in the foot-pad, ear pinna or eye, female guinea pigs inoculated by the genital route and rabbits inoculated in the eye. As well as forming models for the establishment oflatent infections, the latter species have proved to provide models for reactivation and recurrence either spontaneously (guinea pigs) or following epi- 
HSV in the latent state
Once latency is established the virus becomes quiescent in the form of non-integrated, probably circular, nucleosome-bound DNA (Efstathiou et al., 1986; Mellerick & Fraser, 1987) . The apparent absence of genomic termini is consistent with the proposed circular form of HSV DNA during latency. Transcription of the latent DNA is limited to a single region of the genome, giving rise to species of RNA which are antisense to an HSV alpha-gene and these are termed latency-associated transcripts (LAT) (Stevens et al., 1987) , the predominant one of which is a spliced 8 kb product known as a major LAT (Zwaagstra et al., 1990) . In situ hybridization methods using RNA probes antisense to LAT may be used to detect LAT. This method has been used to show that the LAT are confined to ganglionic neuronal nuclei and are present in large copy numbers in the nucleus (Fraser et al., 1992) . Although LAT appear to have a role in reactivation from latency, it appears that the expression of LAT are not essential for the establishment or maintenance ofHSV latency (Steiner Skin Figure 3 . The mouse ear model.
Virus inoculation
HSV-] or2 nephrine iontophoresis (rabbit eye) (reviewed in Field & Brown, 1989) . Taken together, the experimental work carried out in these animals suggests that they accurately model the events that take place in humans during the establishment, maintenance and reactivation from latency; although the timing of events, the quantitative extent of virus replication and its distribution to other anatomical locations (especially CNS tissues) are difficult to compare between different species.
The mouse ear model
A model that has been extensively used in this laboratory for the study of both topical and systemic chemotherapy or chemoprophylaxis for HSV is the mouse ear model ( Fig. 3) . Female BALB/c mice at 3-4 weeks of age are inoculated with a dose usually in the range 10 4-106 p.f.u. ear". The acute infection in the ear may be monitored by observing clinical signs (weight loss, erythema, vesicles and ear paralysis). Inflammation is measured by ear swelling and local virus replication is monitored by titration of tissue homogenates. It has been shown in numerous publications that prompt application of an effective systemic inhibitor such as aciclovir can modulate the development of disease; clinical signs (including inflammation) are reduced and virus replication is suppressed. It was reported, however, that once latent infections are established, continuous antiviral therapy for up to 2 weeks did not affect the ability to reactivate virus from the explanted ganglia on cessation of therapy (Field & De Clercq, 1981) . It was similarly shown that periods of therapy could suppress reactivation, but again this was only effective for the period of treatment and the infection was not eradicated (Blyth et al., 1980) . In an even more comprehensive study using rabbits, Nesburn
Can HSV latency be prevented? Experience with aciciovir provides a pessimistic view on the ability of nucleoside analogues to affect latency
Against this background ofprevious work, especially using aciclovir, two new prodrugs, valaciclovir and famciclovir, were compared in a series of animal model experiments. Surprising differences emerged between the two compounds regarding their ability to affect the establishment of HSV latency. Several recent papers which report the study of valaciclovir and penciclovir in the murine ear pinna infection model are the subject of this review.
Materials and Experimental Procedures

Antiviral compounds
Famciclovir and valaciclovir and the respective metabolic products, penciclovir and aciclovir, were synthesized in the laboratories of SmithKline Beecham (Brentford, UK). The antiviral activities of penciclovir and aciclovir were measured in murine 3T3 cells. The ED so concentrations determined by plaque reduction for penciclovir and aciclovir for HSV-1 (SC16) were 0.02 and 0.01 flg mL-1, respectively and 0.06 and 0.05 fIg mL-i for HSV-2 (Bry) (Thackray & Field, 1996a ).
Mice and virus
All studies were carried out in female BALBIc mice purchased at 3-4 weeks old and infected 1 week later. The laboratory strains of HSV used were HSV-1 (SC16) and HSV-2 (Bry), JVlice were inoculated into the skin of the left ear pinna at a dose of 1 X 10 5 and 2 X 10 4 p.f.u. rnouse" for HSV-1 and HSV-2, respectively. Chemotherapy Antiviral compounds were dissolved in double-distilled deionized water to give a dose of 50 mg kg-1 body weight in 0.1 mL and were administered by oral gavage. Alternatively, the compounds were administered ad libitum in the drinking water at a dose of 1 mg ml..". Mice consumed approximately 150 mg kg day"; the mice showed no distaste for the compounds but most water consumption occurred during the night.
Clinical signs and virus titration
Mice were assessed for signs of disease at daily intervals. Tissues (ear pinna, brain stem, cervical dorsal root and trigeminal ganglia) were removed from groups of mice, homogenized and tested for the presence of infectious virus by titration on EHK cell monolayers, using published methods Thackray & Field, 1996a , 1996b . In order to assess latency, ganglia were explanted into medium for incubation at 37 DC for 5 days (HSV-1) or 10 days (HSV-2). The ganglia were then homogenized and titrated for the presence of infectious virus as described above (Fig. 3 ). These methods are described in detail by Thackray & Field (1996a , 1996b .
Results
The efficacy of famciclovir and valaciclovir in a murine cutaneous immunosuppression model
Initially, experiments were carried out in a model for chronic herpes simplex produced by T cell immunosuppression. JVIice were immunosuppressed by means of cyclosporin treatment on alternate days. HSV-1 (strain SC16) was inoculated into the left ear to create a primary site of virus replication. Famciclovir therapy, given at 50 mg kg-1 by oral gavage or administered in the drinking water at 1 mg mL-l ad libitum (equivalent to approximately 150 mg kg-1 ) was extremely effective and reduced clinical signs including mortality, weight loss and inflammation (measured by skin thickness). Furthermore, infectious virus was cleared from the skin . Valaciclovir administered at identical doses was found to be less effective in the mouse model; in particular, a recurrence of infectious virus occurred in both neural tissue and the skin of the ear within 1 or 2 days of terminating the treatment Field & Thackray, 1996) virus inoculation. The superior effects of famciclovir over valaciclovir were confirmed in mice in which therapy was delayed . Furthermore, the recurrence of infectious virus in the skin and neural tissues was also seen in mice treated from days 5-10 with valaciclovir. As before, no such recurrences were observed in famciclovir-rrcated mice.
Preliminary results suggest an effect on the establishment of HSV latency
Several experiments were carried out using the immunosuppression model described above, and surviving mice from treated and untreated groups were tested 1-6 months after the primary infection for the presence oflatent HSV. The left and right trigeminal ganglia and second, third and fourth cervical ganglia were explanted into culture medium. After 4-5 days the ganglia were homogenized and tested for the presence of infectious virus. All mice that had been untreated during the acute infection yielded HSV from the ganglia. None of the mice that had been treated from 18 h or 22 h post-infection with famciclovir produced reactivated HSV from the ganglia. All groups of mice that had been treated with va1acicloviryielded reactivated HSV, though in some cases there was a reduced yield compared with the controls (AM Thackray & HJ Field, unpublished observations) ( Table 1 ). The heterogeneous nature of the groups of mice assessed, however, made the data very difficult to evaluate and these preliminary results were not published. A comprehensive experiment was then conducted in order to test the hypothesis that famciclovir is superior to va1aciclovir in preventing the establishment of latent infections in mice. Cyclosporin immunosuppression was omitted in the subsequent experiments in order to make the experiments simpler technically and the results easier to interpret.
The effects of chemotherapy on the establishment of HSV~1 latency
A total of 680 mice were infected in the left ear. Chemotherapy with famciclovir or valaciclovir (1 mg mL-1 in the drinking water ad libitum) commenced in groups of mice starting on days 1,2,3,4 or 5 post-inoculation. In all cases the therapy was terminated on day 10 post-inoculation. The results have been published byThackray & Field (1996b). The two compounds differed little in their ability to reduce virus replication in the skin. However, famciclovir was clearly superior in reducing neurological clinical signs and in suppression of virus in the neural tissue examined (brain stem). On cessation of therapy, all mice that had been treated with valaciclovir showed a transient recurrence of infectious virus in the brain stem (but not ear). When the ganglia were assessed using the explant latency test, no mice that had been treated with famciclovir starting on day 3 or earlier showed reactivation (Table 2) and there appeared to be a reduction in the number of mice that scored positive for reactivation, even when the onset of treatment had been delayed until day 5 postinfection. There was also a marked reduction in the proportion of contralateral ganglia that scored positive for Antiviral Chemistry & Chemotherapy Volume 8, Supplement 1 Can HSV lotency be prevented? reactivation, including mice in which the start of treatment was delayed to day 5. In contrast, at least some mice in every group that had been treated with valaciclovir scored positive for reactivation, including those treated from the earliest time (day 1 post-infection) (Thackray & Field, 1996b) .
The effects of chemotherapy on the establishment of HSV-2 latency
A much smaller experiment was conducted to test the effects of the two compounds on HSV-2 in the ear pinna infection model. The virus strain employed was HSV-2 (Ery), which is more neuropathogenic than HSV-1 (SC16). Chemotherapy with famciclovir or valaciclovir, 50 mg kg-1 given by oral gavage twice daily, was started on day 1 post-infection. The results have been published by Thackray & Field (1996a) and show that cessation of valaciclovir (but not famciclovir) therapy was followed by multiple recurrences of infectious virus in the brain stem 1-7 days after therapy was stopped. Groups of 10 mice were tested for latency 6 weeks post-inoculation. All of 10 untreated mice scored positive for latency for both the left and right trigeminal and left cervical dorsal root ganglia; 6 out of 10 mice were also positive for the contralateral cervical ganglia. None of the ganglia from 10 famciclovir-treated mice were positive according to this test for latency (Table 3 ). In constast, 6 of the mice that had received valaciclovir were positive for this test (Table 3) .
The effects of chemotherapy on mice in which latency has already been established
To test whether famciclovir may also have an effect on latent infection that has already been established 1-4 months previously in the absence of chemotherapy, mice were treated continuously for a period of 2 weeks by placing valaciclovir or famciclovir in the drinking water. There was no apparent reduction in the incidence of latency and Adapted from Thackray & Field (19960) . a Mice (n = 10) were treated from 22 h post-infection for 5 days with famciclovir or volaciclovir, 50 mg kg-1 b.d. given by oral gavage. A control group of mice did not receive either agent. b Numbers represent positive results for the latency test (n = 10). Ganglia were explanted 1 month later and incubated for 10 days before homogenization. Thackray & Field (1996b) .
a Mice were treated for 2 weeks with either famciclovir or valaciclovir, 1 mg ml,", in the drinking water. The period of treatment was 4-6 months after infectian.
b Numbers are the proportion of mice yielding virus after explant reactivation.
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Right TG left CIII nase/trypsin and infectious centres were determined by plating individual cells on monolayers of susceptible cells. Finally, sections of ganglia and brain stem were tested by means of in situ hybridization using a digoxigenin-labelled riboprobe designed to detect the major LAT. The preliminary results of this analysis have been reported (Thackray and Field, 1996c) . Whereas the detailed numerical data are extremely interesting and will be published in the near future (Field and Thackray, manuscript in preparation) the overall results are very clear. Famciclovir therapy starting within 2-3 days of virus inoculation results in a significant reduction of cells that score positive for HSV latency, as determined by any method. However, a small number of latency-positive cells were seen in all groups, even among those in which therapy commenced as early as day 1 postinoculation.
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all 10 mice in each of three groups were positive for reactivation from the left trigeminal and cervical ganglia (Table 4 ).
Discussion
The assessment of latency by means of more sensitive and semi-quantitative tests A further experiment was conducted in which HSV-1 (SC16) was inoculated into the ear and treatment with famciclovir or valaciclovir (50 mg kg-1 by twice daily oral gavage) commenced on days 1,2,3,4 or 5 post-inoculation. The ganglia were subsequently tested for latency using a variety of different methods (Fig. 4) . The ganglia were assessed using the conventional explant test as above. Ganglia from other mice were co-cultivated with susceptible indicator cells for up to 73 days. Ganglia from additional mice were disaggregated by means of collage-
The consensus was that if an effective therapy commenced before, at the time of, or very soon after virus inoculation, then latency may be prevented. The period for which therapy can be delayed in order to prevent latency in mice depends on dose, but for moderate inocula it is unlikely to be greater than 1-2 days (Klein et al., 1978 (Klein et al., , 1979 Pavan-Langston et al., 1979; Field & De Clercq, 1981) . It is very difficult to relate these findings in animal models, which employ defined inocula containing relatively large numbers of infectious virions, to the natural exposure encountered in humans. Although we are generally ignorant about the dose, it is presumably relatively small and it is likely that a period of replication ofl-2 days in the skin precedes the virus travelling to the ganglia. The relative distance between skin and ganglia is approximately IO-fold greater in humans than mouse, suggesting that the window of opportunity for commencing therapy may be as long as several days in humans. In any case, the relative effects of suppressing virus replication in the skin/mucus membrane and ganglionic tissue is unknown. From the results of the studies described in this review it appears that the answer to the question Can HSV latency be prevented using conventional nucleoside analogue therapy?' in practical terms is clearly, 'no'. However, the effects of famciclovir on neurological virus infection appear to be superior to valaciclovir in the murine model and, using a simple explantation test for reactivation in vitro, the ability of these cultures to yield infectious virus was significantly reduced, even when famciclovir therapy had been withheld for several days. Given that aciclovir and penciclovir have similar potency against HSV in tissue culture and the fact that the plasma concentrations of the same two compounds are similar in mice after oral administration of the prodrugs, this allows us cautious optimism that the effects of famciclovir on neural HSV infection in humans may be superior to compounds previously employed and justifies clinical trials in humans which focus on the effects of early famciclovir therapy on primary herpes infections. In due course, these studies should prove whether or not such early chemotherapy affects the subsequent frequency and severity of recurrent episodes of disease.
